Integrating clinical services for HIV, tuberculosis, and cryptococcal disease in the developing world: A step forward with 2 novel diagnostic tests

Journal of the International Association of Providers of AIDS Care

Volumn 12, Issue 5, 2013, Pages 301-305

  Vijayan, Tara ^a   Klausner, Jeffrey D ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cryptococcosis; point of care diagnostics; service integration; tuberculosis

Indexed keywords

FLUCONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL EFFECTIVENESS; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; DEVELOPING COUNTRY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

CRYPTOCOCCOSIS; POINT-OF-CARE DIAGNOSTICS; SERVICE INTEGRATION; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; CRYPTOCOCCOSIS; DELIVERY OF HEALTH CARE, INTEGRATED; DEVELOPING COUNTRIES; HIV INFECTIONS; HUMANS; MICROBIOLOGICAL TECHNIQUES; POINT-OF-CARE SYSTEMS; TUBERCULOSIS;

EID: 84884678708     PISSN: 23259574     EISSN: 23259582     Source Type: Journal    
DOI: 10.1177/2325957413500472     Document Type: Review

References (33)

1. Gupta A, Nadkarni G, Yang WT, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One. 2011 ; 6 (12). e28691
2. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008 ; 22 (15). 1897-1908
3. Making A Difference: Global Fund Results Report 2011. Switzerland: Geneva ; 2011 :
4. WHO Report: Global Tuberculosis Control 2011. Geneva, Switzerland: World Health Organization ; 2011 :
5. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009 ; 23 (4). 525-530
6. Jarvis JN, Boulle A, Loyse A, et al. High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. AIDS. 2009 ; 23 (9). 1182-1183
7. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008 ; 8 (8). 516-523
8. Lawn SD, Bekker LG, Myer L, Orrell C, Wood R. Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS. 2005 ; 19 (17). 2050-2052
9. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010 ; 10 (4). 251-261
10. Roy M, Chiller T. Preventing deaths from cryptococcal meningitis: from bench to bedside. Expert Rev Anti Infect Ther. 2011 ; 9 (9). 715-717
11. Lawn SD, Wood R. Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis. 2011 ; 204 (suppl 4). S1159 - S1167
12. Jarvis JN, Percival A, Bauman S, et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis. 2011 ; 53 (10). 1019-1023
13. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis. 2012 ; 12 (3). 201-209
14. Liechty CA, Solberg P, Were W, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health. 2007 ; 12 (8). 929-935
15. Meya DB, Manabe YC, Castelnuovo B, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis. 2010 ; 51 (4). 448-455
16. Rajasingham R, Meya DB, Boulware DR. Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr. 2012 ; 59 (5). e85 - e91
17. Saha DC, Xess I, Biswas A, Bhowmik DM, Padma MV. Detection of Cryptococcus by conventional, serological and molecular methods. J Med Microbiol. 2009 ; 58 (pt 8). 1098-1105
18. Lindsley MD, Mekha N, Baggett HC, et al. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis. 2011 ; 53 (4). 321-325
19. Stevens W. Washington DC: University of Witswatersand ; 2012 :
20. Rajasingham R, Meya D, Rolfes M, Birkenkamp K, Boulware DR International AIDS Society Conference. Washington DC: ; 2012 :
21. Jarvis JN, Govender N, Chiller T, et al. Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation. J Int Assoc Physicians AIDS Care (Chic). 2012 ; 11 (6). 374-379
22. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011 ; 377 (9776). 1495-1505
23. Lawn SD. Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review. BMC Infect Dis. 2012 ; 12: 103
24. Lawn SD, Wood R. Point-of-care urine antigen screening tests for tuberculosis and cryptococcosis: potential for mortality reduction in antiretroviral treatment programs in Africa. Clin Infect Dis. 2012 ; 54 (5). 739-740
25. Wood R, Lawn SD. Challenges facing lipoarabinomannan urine antigen tests for diagnosing HIV-associated tuberculosis. Expert Rev Mol Diagn. 2012 ; 12 (6). 549-551
26. Peter JG, Theron G, Dheda K. Urine antigen test for diagnosis of HIV-associated tuberculosis. Lancet Infect Dis. 2012 ; 12 (11). 825
27. Dowdy DW, Gounder CR, Corbett EL, Ngwira LG, Chaisson RE, Merritt MW. The ethics of testing a test: randomized trials of the health impact of diagnostic tests for infectious diseases. Clin Infect Dis. 2012 ; 55 (11). 1522-1526
28. Steingart KR, Flores LL, Dendukuri N, et al. Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: an updated systematic review and meta-analysis. PLoS Med. 2011 ; 8 ( 8 ):
29. Commerical Serodiagnostic Tests for the Diagnosis of Tuberculosis. Geneva, Switzerland: World Health Organization ; 2011 :
30. Sun D, Dorman S, Shah M, Manabe Y, Dowdy D Washington DC: ; 2012 :
31. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Clinical significance of lipoarabinomannan (LAM) detection in urine using a low-cost point-of-care diagnostic assay for HIV-associated tuberculosis. AIDS. 2012 ; 26 (13). 1635-1643
32. Sweeney S, Obure CD, Maier CB, Greener R, Dehne K, Vassall A. Costs and efficiency of integrating HIV/AIDS services with other health services: a systematic review of evidence and experience. Sex Transm Infect. 2012 ; 88 (2). 85-99
33. Jani IV, Sitoe NE, Alfai ER, et al. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet. 2011 ; 378 (9802). 1572-1579